awmsg logo



quetiapine (Seroquel XL®)


Reference No. 252

Publication date:
15/09/2009


Appraisal information

quetiapine (Seroquel XL®) prolonged-release tablet


Company: AstraZeneca UK Ltd
BNF category: Central nervous system
NMG meeting date: 15/07/2009
AWMSG meeting date: 12/08/2009
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1509
Ministerial ratification: 11/09/2009

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Quetiapine prolonged-release tablets (Seroquel XL®) are recommended as an option for use within NHS Wales for the treatment of schizophrenia in adults. In order to limit errors, prolonged-release quetiapine should be prescribed by brand name, as Seroquel XL®. AWMSG is of the opinion that quetiapine prolonged-release tablets (Seroquel XL®) may be suitable for shared care within NHS Wales. Quetiapine prolonged-release tablets (Seroquel XL®) are not endorsed for the treatment of manic episodes associated with bipolar disorder within NHS Wales. AstraZeneca UK Ltd is not in a position to progress a submission to AWMSG for its appraisal in this indication. As a result, AWMSG cannot provide advice to the Minister for Health and Social Services.
Final Appraisal Recommendation (FAR)
Download